%0 Journal Article %T Cabozantinib in advanced renal cell carcinoma: a METEOR impact on clinical practice %A Grassi, Paolo %A Verzoni, Elena %A Mennitto, Alessia %A Procopio, Giuseppe %J Translational Andrology and Urology %D 2016 %B 2016 %9 %! Cabozantinib in advanced renal cell carcinoma: a METEOR impact on clinical practice %K %X Final results from the randomised phase III METEOR study have been recently published and confirmed the superiority of cabozantinib over everolimus in patients with advanced or metastatic clear-cell renal cell carcinoma (mRCC) who received at least one previous VEGFR tyrosine-kinase inhibitor (TKI) (1). %U https://tau.amegroups.org/article/view/12807 %V 5 %N 6 %P 974-976 %@ 2223-4691